Abstract 101P
Background
The proven success of combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy in estrogen receptor-positive (ER+) metastatic breast cancer has prompted evaluation of this therapeutic approach in patients with early-stage disease. Notably, the CDK4/6i abemaciclib and ribociclib, but not palbociclib, improved invasive disease-free survival in the adjuvant setting in clinical trials. These data suggest that complex assessment of breast tumor genomic, clinical and pathological characteristics, and CDK4/6i efficacy and toxicity profiles, will be required for a better refinement of indication for specific CDK4/6i in the early-stage setting. In the present study, we aimed to identify and characterize the early breast cancer patient population that will benefit the most from each CDK4/6i by using patient-derived breast cancer organoids.
Methods
We developed a repository of patient-derived organoids (PDOs) from ER+ primary breast tumor resections. RNA, DNA, and protein were purified from PDOs and paired fresh frozen tissue, for validation of organoids characteristics compared to the original tumor. To fully characterize our PDOs, we performed RNA sequencing (RNAseq), single nucleotide polymorphism/copy number variation (SNP/CNV) array, live-cell imaging, quantitative real-time PCR, and drug testing. Efficacy of CDK4/6i on selected PDOs was evaluated by viability and cytotoxicity assays, and gene expression profile in sensitive vs. resistant PDOs was compared by RNAseq.
Results
We found that various PDOs retained the main alterations of the original tumor, by SNP/CNV arrays. Furthermore, we were able to rank the organoids based on the response (IC50) to abemaciclib. By RNAseq and RT-qPCR we identified specific genes that might be linked with differential responses to CDK4/6i. Among these, we found concomitant CDK6 overexpression and, surprisingly, cyclin D1 downregulation in PDOs with higher IC50 towards CDK4/6i in both innate and acquired resistance models.
Conclusions
Our data suggest that high-CDK6 and low-cyclin D1 expression might be a biomarker for selection of patients with poor response to CDK4/6i abemaciclib in the adjuvant setting.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Ethics Committee of the Region of Southern Denmark and Copenhagen and Frederiksberg Counties; Danish Data Protection Agency and the Danish Breast Cancer Cooperative Group.
Funding
Danish Cancer Society; Sygeforsikring Danmark; Danmarks 3R-Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract